News

FDA approves IntraBio's AQNEURSA as first treatment for ataxia-telangiectasia

What's the news? On 18 September 2026 the US Food and Drug Administration (FDA) approved AQNEURSA (levacetylleucine) as an oral suspension, making it the first approved treatment for ataxia in people with ataxia-telangiectasia (A-T). The approval covers adults and children weighing at least 15 kg (about 33 pounds). A-T is a rare inherited condition that progressively damages the nervous and immune systems; ataxia is the difficulty coordinating movement that it causes. AQNEURSA builds on IntraBio's earlier 2024 approval for Niemann-Pick disease type C, another rare neurological disorder.

Why it matters: Before this decision, no drug specifically treated the ataxia of A-T. Levacetylleucine is a modified form of the amino acid leucine that patients take daily by mouth. The FDA's decision was supported by a randomised, double-blind, placebo-controlled crossover study of 73 patients aged four years and older with confirmed A-T. The drug was granted Orphan Drug Designation and Priority Review, reflecting how few treatment options exist for this ultra-rare disease. The FDA advises that AQNEURSA should not be used together with N-acetyl-DL-leucine, and that patients taking certain other drugs should be monitored more closely while on it.

Read more: US Food and Drug Administration, 18 September 2026

More top stories